Rona pays for rights to Sanofi's siRNA portfolio and platform

25 July 2022

Chinese RNA company Rona Therapeutics has announced a deal with French pharma major Sanofi (Euronext: SAN).

The Shanghai-based company has acquired worldwide exclusive access to Sanofi's siRNA platform of chemical modification and delivery moiety as well as rights to four pre-clinical candidates for undisclosed targets.

"Rona plans to quickly advance the development of these programs in metabolic, neurological and ocular diseases to unlock the potential of siRNA therapeutics"These rights will enable Rona to significantly expand and accelerate its siRNA portfolio in both liver and non-liver applications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK